Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study

DF Heigener, YL Wu, N van Zandwijk, P Mali… - Lung Cancer, 2011 - Elsevier
Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …
被引用次数：40 相关文章

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.

DF Heigener, YL Wu, N van Zandwijk… - Lung Cancer …, 2011 - europepmc.org
Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

[引用][C] Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study

DF HEIGENER, YL WU, N VAN ZANDWIJK… - Lung …, 2011 - pascal-francis.inist.fr
Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup
analyses from the TRUST study CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study

DF Heigener, YL Wu… - Lung cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study

DF Heigener, YL Wu, N van Zandwijk, P Mali… - Lung …, 2011 - lungcancerjournal.info
Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study

DF Heigener, YL Wu, N van Zandwijk, P Mali… - Lung Cancer, 2011 - infona.pl
Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

[引用][C] Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study

DF Heigener, YL Wu, N van Zandwijk, P Mali… - 2011

[引用][C] Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study

DF Heigener, YL Wu, N van Zandwijk, P Mali… - 2011